Genmab through collaboration with Blink\nbiomedicals raised a whopping $503 Million through an American initial public\noffering (IPO) all this got revealed on Friday during an event. Genmab also\nlaunched an up to $200 million-per-product cancer therapy with Blink\nbiomedicals.<\/p>\n\n\n\n
Blink biomedicals got a license approved by\nGenmab exclusively for antibodies targeting CD47, which Genmab plans to combine\nwith its duo body platform technology to produce new bispecific antibodies for\nfighting cancer. Genmab CEO Jan van de Winkel, Ph.D. gave his words about this\nCD47 stating that \u201cCD47 has shown\npotential as the target for cancer and we believe that the bispecific approach\nmay open up a potential for differentiated therapies,\u201d<\/em> <\/p>\n\n\n\n Blink biomedicals is a company based in\nMarseille, France that is privately-held and focuses primarily on the\ndevelopment process along with some new explorations and introductions in the\nfield of therapeutic antibodies in oncology and immuno-oncology.<\/p>\n\n\n\n Blink biomedicals are reported to receive\n$2.25 million upfront, and up to $200 million-per-product for developmental,\nregulatory, and commercial milestones sort of work. Blink biomedicals also have\nroyalties tied to their name for some previous works as well. \u201cAdvancing\nour pipeline of differentiated and the well-tolerated antibodies,\u201d<\/em> stated\nGenmab, for their collaboration with Blink biomedicals. Genmab highlighted this\ncollaboration as a thing of priority.\n\nNot\njust with Blink biomedicals, Genmab is also working with other big companies as\nwell. Genmab is currently working with Seattle genetics for the clinical\ncandidate, tisotumab vedotin, which is in Phase II in cervical cancer, ovarian\ncancer, and solid cancers.\n\n\n\n<\/p>\n","protected":false},"excerpt":{"rendered":" Genmab through collaboration with Blink biomedicals raised a whopping $503 Million through an American initial public offering (IPO) all this got revealed on Friday during an event. Genmab also launched an up to $200 million-per-product cancer therapy with Blink biomedicals. Blink biomedicals got a license approved by Genmab exclusively for antibodies targeting CD47, which Genmab […]<\/p>\n","protected":false},"author":2,"featured_media":342,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_mi_skip_tracking":false},"categories":[3,5,2,1],"tags":[128,110,15,112],"_links":{"self":[{"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/posts\/341"}],"collection":[{"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/comments?post=341"}],"version-history":[{"count":1,"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/posts\/341\/revisions"}],"predecessor-version":[{"id":343,"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/posts\/341\/revisions\/343"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/media\/342"}],"wp:attachment":[{"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/media?parent=341"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/categories?post=341"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/tags?post=341"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}